Current Pharmacologic Strategies for Treatment of Intractable Epilepsy in Children

다국어 초록 (Multilingual Abstract)

Epileptic encephalopathy (EE) is a devastating pediatric disease that features medically resistant seizures, which can contribute to global developmental delays. Despite technological advancements in genetics, the neurobiological mechanisms of EEs are not fully understood, leaving few therapeutic options for affected patients. In this review, we introduce the most common EEs in pediatrics (i.e., Ohtahara syndrome, Dravet syndrome, and Lennox-Gastaut syndrome) and their molecular mechanisms that cause excitation/inhibition imbalances. We then discuss some of the essential molecules that are frequently dysregulated in EEs. Specifically, we explore voltage-gated ion channels, synaptic transmission-related proteins, and ligand-gated ion channels in association with the pathophysiology of Ohtahara syndrome, Dravet syndrome, and Lennox-Gastaut syndrome. Finally, we review currently available antiepileptic drugs used to treat seizures in patients with EEs. Since these patients often fail to achieve seizure relief even with the combination therapy, further extensive research efforts to explore the involved molecular mechanisms will be required to develop new drugs for patients with intractable epilepsy.

참고문헌 (Reference)

1 Kruger LC, "β1-C121W is down but not out : epilepsy-associated Scn1b-C121W results in a deleterious gain-of-function" 36 : 6213-6224, 2016

2 de Lera Ruiz M, "Voltage-gated sodium channels: structure, function, pharmacology, and clinical indications" 58 : 7093-7118, 2015

3 Catterall WA, "Voltage-gated calcium channels" 3 : a003947-, 2011

4 Wu Y, "Vigabatrin induces tonic inhibition via GABA transporter reversal without increasing vesicular GABA release" 89 : 2021-2034, 2003

5 Farrant M, "Variations on an inhibitory theme : phasic and tonic activation of GABAA receptors" 6 : 215-229, 2005

6 Davis R, "Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy" 47 : 332-372, 1994

7 Auvin S, "Use of perampanel in children and adolescents with Lennox-Gastaut Syndrome" 74 : 59-63, 2017

8 Smith EH, "Toward a mechanistic understanding of epileptic networks" 16 : 97-, 2016

9 Lynch BA, "The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam" 101 : 9861-9866, 2004

10 Marini C, "The genetics of Dravet syndrome" 52 (52): 24-29, 2011

11 McTague A, "The genetic landscape of the epileptic encephalopathies of infancy and childhood" 15 : 304-316, 2016

12 Eriksson AS, "The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study" 39 : 495-501, 1998

13 Dravet C, "The core Dravet syndrome phenotype" 52 (52): 3-9, 2011

14 Du J, "The K+ channel, Kv2.1, is apposed to astrocytic processes and is associated with inhibitory postsynaptic membranes in hippocampal and cortical principal neurons and inhibitory interneurons" 84 : 37-48, 1998

15 Custer KL, "Synaptic vesicle protein 2 enhances release probability at quiescent synapses" 26 : 1303-1313, 2006

16 Verhage M, "Synaptic assembly of the brain in the absence of neurotransmitter secretion" 287 : 864-869, 2000

17 Heine M, "Surface traffic in synaptic membranes" 970 : 197-219, 2012

18 Kleckner NW, "Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate : insights into the mechanism of action" 289 : 886-894, 1999

19 Catterall WA, "Structure and regulation of voltage-gated Ca2+ channels" 16 : 521-555, 2000

20 Yelshanskaya MV, "Structural bases of noncompetitive inhibition of AMPA-subtype ionotropic glutamate receptors by antiepileptic drugs" 91 : 1305-1315, 2016

21 Quilichini PP, "Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABAA-receptor channels" 47 : 704-716, 2006

22 Chiron C, "Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group" 356 : 1638-1642, 2000

23 Cheah CS, "Specific deletion of Nav1.1 sodium channels in inhibitory interneurons causes seizures and premature death in a mouse model of Dravet syndrome" 109 : 14646-14651, 2012

24 Wallace RH, "Sodium channel α1-subunit mutations in severe myoclonic epilepsy of infancy and infantile spasms" 61 : 765-769, 2003

25 Glauser T, "Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome" 70 : 1950-1958, 2008

26 Perucca E, "Rufinamide : clinical pharmacokinetics and concentration-response relationships in patients with epilepsy" 49 : 1123-1141, 2008

27 Yu FH, "Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy" 9 : 1142-1149, 2006

28 Reid CA, "Reduced dendritic arborization and hyperexcitability of pyramidal neurons in a Scn1b-based model of Dravet syndrome" 137 : 1701-1715, 2014

29 Naylor DE, "Rapid surface accumulation of NMDA receptors increases glutamatergic excitation during status epilepticus" 54 : 225-238, 2013

30 Ng YT, "Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome" 77 : 1473-1481, 2011

31 Bialer M, "Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V)" 43 : 11-58, 2001

32 Fiest KM, "Prevalence and incidence of epilepsy : A systematic review and meta-analysis of international studies" 88 : 296-303, 2017

33 Hanada T, "Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy" 52 : 1331-1340, 2011

34 Raimondi A, "Overlapping role of dynamin isoforms in synaptic vesicle endocytosis" 70 : 1100-1114, 2011

35 Wirrell EC, "Optimizing the diagnosis and management of Dravet syndrome : recommendations from a north American consensus panel" 68 : 18-34, 2017

36 Korff CM, "Ohtahara syndrome or early-onset West syndrome? A case with overlapping features and favorable response to vigabatrin" 16 : 753-757, 2012

37 Ohtahara S, "Ohtahara syndrome : with special reference to its developmental aspects for differentiating from early myoclonic encephalopathy" 70 (70): S58-S67, 2006

38 Lachance-Touchette P, "Novel α1 and γ2 GABAA receptor subunit mutations in families with idiopathic generalized epilepsy" 34 : 237-249, 2011

39 Brown DA, "Neural KCNQ(Kv7)channels" 156 : 1185-1195, 2009

40 Gilchrist J, "Nav1.1 modulation by a novel triazole compound attenuates epileptic seizures in rodents" 9 : 1204-1212, 2014

41 Toonen RF, "Munc18-1 in secretion : lonely Munc joins SNARE team and takes control" 30 : 564-572, 2007

42 Toonen RF, "Munc18-1 expression levels control synapse recovery by regulating readily releasable pool size" 103 : 18332-18337, 2006

43 Reid CA, "Multiple molecular mechanisms for a single GABAA mutation in epilepsy" 80 : 1003-1008, 2013

44 Schroeder BC, "Moderate loss of function of cyclic-AMP-modulated KCNQ2/KCNQ3 K+ channels causes epilepsy" 396 : 687-690, 1998

45 Yamashita S, "Mislocalization of syntaxin-1 and impaired neurite growth observed in a human iPSC model for STXBP1-related epileptic encephalopathy" 57 : e81-6, 2016

46 Rogawski MA, "Mechanisms of action of antiseizure drugs and the ketogenic diet" 2016

47 Ben-Menachem E, "Mechanism of action of vigabatrin : correcting misperceptions" 192 : 5-15, 2011

48 Rho JM, "Mechanism of action of the anticonvulsant felbamate : opposing effects on N-methyl-D-aspartate and γ-aminobutyric acidA receptors" 35 : 229-234, 1994

49 Trimmer JS, "Localization of voltage-gated ion channels in mammalian brain" 66 : 477-519, 2004

50 Fukuyama K, "Levetiracetam inhibits neurotransmitter release associated with CICR" 518 : 69-74, 2012

51 Arzimanoglou A, "Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology" 8 : 82-93, 2009

52 Trevathan E, "Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome" 339 : 851-852, 1998

53 Misonou H, "Kv2.1: a voltage-gated K+channel critical to dynamic control of neuronal excitability" 26 : 743-752, 2005

54 Weckhuysen S, "KCNQ2 encephalopathy : emerging phenotype of a neonatal epileptic encephalopathy" 71 : 15-25, 2012

55 Schwarz JR, "KCNQ channels mediate IKs, a slow K+ current regulating excitability in the rat node of Ranvier" 573 : 17-34, 2006

56 Saitsu H, "Jasper’s basic mechanisms of the epilepsies" National Center for Biotechnology Information 2012

57 Aaberg KM, "Incidence and prevalence of childhood epilepsy : a nationwide cohort study" 139 : e20163908-, 2017

58 Fisher RS, "ILAE official report : a practical clinical definition of epilepsy" 55 : 475-482, 2014

59 Petroff OA, "Human brain γ-aminobutyric acid levels and seizure control following initiation of vigabatrin therapy" 67 : 2399-2404, 1996

60 Reiner A, "Glutamatergic signaling in the central nervous system : ionotropic and metabotropic receptors in concert" 98 : 1080-1098, 2018

61 Allen NM, "Genetic potassium channel-associated epilepsies : Clinical review of the Kv family" 24 : 105-116, 2020

62 Carvill GL, "GABRA1 and STXBP1 : novel genetic causes of Dravet syndrome" 82 : 1245-1253, 2014

63 Qu S, "GABAA receptor β3 subunit mutation D120N causes Lennox-Gastaut syndrome in knock-in mice" 2020

64 Benarroch EE, "GABAA receptor heterogeneity, function, and implications for epilepsy" 68 : 612-614, 2007

65 Steinhoff BJ, "First clinical experiences with perampanel-the Kork experience in 74 patients" 55 (55): 16-18, 2014

66 Bourgeois BF, "Felbamate" 4 : 3-8, 1997

67 Engel J Jr, "Excitation and inhibition in epilepsy" 23 : 167-174, 1996

68 Janve VS, "Epileptic encephalopathy de novo GABRB mutations impair γ-aminobutyric acid type A receptor function" 79 : 806-825, 2016

69 Beghi E, "Epidemiologic aspects : lost in transition" 55 (55): 3-7, 2014

70 Pisani A, "Electrophysiological actions of felbamate on rat striatal neurones" 116 : 2053-2061, 1995

71 Dressler A, "Efficacy and tolerability of the ketogenic diet in Dravet syndrome-Comparison with various standard antiepileptic drug regimen" 109 : 81-89, 2015

72 Muramatsu K, "Efficacy and tolerability of levetiracetam for pediatric refractory epilepsy" 39 : 231-235, 2017

73 Yamatogi Y, "Early-infantile epileptic encephalopathy with suppression-bursts, Ohtahara syndrome; its overview referring to our 16 cases" 24 : 13-23, 2002

74 Cazorla MR, "Early infantile epileptic encephalopathy with unusual favourable outcome" 32 : 673-676, 2010

75 Kwan P, "Early identification of refractory epilepsy" 342 : 314-319, 2000

76 Liu Y, "Dravet syndrome patient-derived neurons suggest a novel epilepsy mechanism" 74 : 128-139, 2013

77 Guerrini R, "Dravet syndrome : the main issues" 16 (16): S1-S4, 2012

78 Vassella F, "Double-blind study on the anti-convulsive effect of phenobarbital and valproate in the Lennox syndrome" 108 : 713-716, 1978

79 Warner TA, "Differential molecular and behavioural alterations in mouse models of GABRG2 haploinsufficiency versus dominant negative mutations associated with human epilepsy" 25 : 3192-3207, 2016

80 Stefani A, "Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies" 147 : 115-122, 1997

81 Speca DJ, "Deletion of the Kv2.1 delayed rectifier potassium channel leads to neuronal and behavioral hyperexcitability" 13 : 394-408, 2014

82 Camfield PR, "Definition and natural history of Lennox-Gastaut syndrome" 52 (52): 3-9, 2011

83 van Vliet EA, "Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy" 50 : 422-433, 2009

84 Claes L, "De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy" 68 : 1327-1332, 2001

85 Kodera H, "De novo GABRA1 mutations in Ohtahara and West syndromes" 57 : 566-573, 2016

86 Auvin S, "Current understanding and neurobiology of epileptic encephalopathies" 92 : 72-89, 2016

87 Prince DA, "Control mechanisms in cortical epileptogenic foci. “Surround” inhibition" 16 : 194-202, 1967

88 Rossignol E, "Cav2.1 ablation in cortical interneurons selectively impairs fast-spiking basket cells and causes generalized seizures" 74 : 209-222, 2013

89 Kim HJ, "Adjunctive levetiracetam treatment in pediatric Lennox-Gastaut syndrome" 51 : 527-531, 2014

90 Otto JF, "A spontaneous mutation involving Kcnq2 (Kv7.2) reduces M-current density and spike frequency adaptation in mouse CA1 neurons" 26 : 2053-2059, 2006

91 Schmidt D, "A risk-benefit assessment of therapies for Lennox-Gastaut syndrome" 22 : 467-477, 2000

92 Chhun S, "A prospective open-labeled trial with levetiracetam in pediatric epilepsy syndromes : continuous spikes and waves during sleep is definitely a target" 20 : 320-325, 2011

93 Thiffault I, "A novel epileptic encephalopathy mutation in KCNB1 disrupts Kv2.1 ion selectivity, expression, and localization" 146 : 399-410, 2015

94 Poisson M, "A new type of anticonvulsant, stiripentol. Pharmacological profile and neurochemical study" 34 : 199-204, 1984

95 Meehan AL, "A new mechanism for antiepileptic drug action : vesicular entry may mediate the effects of levetiracetam" 106 : 1227-1239, 2011

96 Patino GA, "A functional null mutation of SCN1B in a patient with Dravet syndrome" 29 : 10764-10778, 2009

97 Sun Y, "A deleterious Nav1.1 mutation selectively impairs telencephalic inhibitory neurons derived from Dravet Syndrome patients" 5 : e13073-, 2016